Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.93%
#3 Glidr Glidr +36.87%
#4 MowCat MowCat +27.93%
#5 Humanity Humanity +27.03%
#6 Codatta Codatta +18.91%
#7 Collector Crypt Collector Crypt +18.23%
#8 Walrus Walrus +18.21%
#9 Provenance Blockchain Provenance Blockchain +17.26%
#10 Enso Enso +16.84%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Classifica tra le azioni #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Prezzo delle azioni
$1.73
Ultima sincronizzazione: 2025-06-17
Capitalizzazione di mercato
$2.55M
Variazione (1 giorno)
-0.29%
Variazione (1 anno)
0.00%
Paese
US
Scambia Eiger BioPharmaceuticals, Inc. (EIGR)

Categoria

Healthcare
Ricavi di Eiger BioPharmaceuticals, Inc. (EIGR)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Eiger BioPharmaceuticals, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Eiger BioPharmaceuticals, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE